welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Microlin Bio to Acquire Nucleic Acid Therapeutic Assets of Marina Biotech
Microlin Bio, Inc., a development stage biotechnology company focused on the development of microRNA based therapeutics for cancer, and Marina Biotech, Inc., a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced that the companies have executed a term sheet under which Microlin intends to acquire Marina’s nucleic acid therapeutics assets.

expertly curated content related to this topic
-
Genetic Counseling 101With many rare diseases there is often a...
-
justin slagelCEO S.L.A Pharma...
-
Hisham Hussan, MDSpecialties/Interests: Gastroenterology,...
-
Marina Biotech Announces $1.1 MM Convertible Preferred Stock FinancingMarina Biotech, Inc. ( OTCQB : MRNA ), a...
-
UPMC MercyPatient Resource: Center for Counseling...
-
Osamu ItanoOsamu Itano works in departement of Gas...